Top 50 Ai For Computational Biology

Synthia is a decentralized AI platform designed to streamline computational biology by automating data handling and generating code on demand. It addresses inefficiencies in scientific research by providing universal data compatibility, dynamic computing power, and continuous expert assistance, enabling faster and more accurate analysis.

Heureka provides an AI-powered platform that helps researchers accelerate scientific discovery by generating data-driven hypotheses. Their tools also include bioinformatics analysis and interpretation software to expedite computational biology research, as well as a writing tool for research-related documents.

Genbio AI develops multiscale AI foundation models designed to decode and simulate human biology. The company is building toward an interactive, programmable virtual cell, referred to as an AI-Driven Digital Organism (AIDO). This technology aims to accelerate breakthroughs across medicine, biotech, and life sciences through advanced biological simulation.

This company accelerates small molecule drug discovery by integrating molecular physics simulations with AI-driven computational methods. They offer an intuitive, no-code AI assistant, Balto, for accessible drug discovery workflows including data retrieval, molecular profiling, and ligand docking. Additionally, they provide code-based API access for advanced users needing large-scale docking, free energy calculations, and molecular analysis.

NeuralNet Biotech uses computational biology and machine learning to analyze complex biological data, accelerating the discovery and optimization of biological processes. Our platform identifies predictive biomarkers and designs novel biotechnological solutions, de-risking early-stage research for drug discovery and bioprocess development.

Tamarind Bio provides a unified platform for computational protein engineering, enabling the design and optimization of antibodies, enzymes, peptides, and small molecules. The service integrates state-of-the-art AI and physics-based tools like AlphaFold and RFdiffusion through an accessible interface. This allows scientists to rapidly predict structures, redesign sequences, and optimize developability properties at massive scale without complex setup.

MoleculeMind is an AI-driven biotech company that utilizes advanced algorithms for high-precision protein structure prediction, directed mutagenesis, and de novo protein design. The platform accelerates drug development and industrial applications by enabling rapid identification and optimization of proteins, addressing inefficiencies in traditional biotechnological processes.

DeepBiome Therapeutics is developing a drug discovery platform that utilizes advanced computational biology and machine learning to identify novel therapeutic compounds. This approach addresses the inefficiencies in traditional drug development processes, significantly reducing time and costs associated with bringing new drugs to market.

310 AI develops a generative AI engine focused on making programmable biology a reality. The platform specializes in text-to-protein generation using a foundational molecular programming model. This technology translates functional descriptions directly into novel protein sequences for biological applications.

Boltz provides an AI‑driven platform that accelerates drug discovery by enabling rapid, large‑scale virtual screening of small molecules and protein designs, delivering near‑FEP affinity predictions up to 1,000× faster than traditional methods. Its modular agents—Boltz‑1 for all‑atom co‑folding, Boltz‑2 for ultra‑fast affinity prediction, and BoltzGen for universal binder design—integrate experimental feedback to continuously improve model accuracy for pharmaceutical, biotech, and academic research.

This company uses AI-driven protein design to optimize the production of biological molecules and microbes. Their technology enables enterprises to design more stable and efficient enzymes for applications in synthetic biology, food, cosmetics, and environmental protection.

Atomic AI develops next-generation RNA-centric medicines using machine learning and structural biology. Their ATOM-1 foundation model provides highly precise predictions of three-dimensional RNA structure, enabling access to previously unreachable therapeutic targets. The proprietary R&D platform integrates deep learning models with purpose-built wet-lab assays to accelerate drug discovery.

Synteny develops frontier AI, called MANIFOLD™, to address the challenge of molecular recognition in biology. The platform unifies sequence, structure, and physics data to learn the fundamental laws governing biological cognition. This capability transforms molecular recognition from an intractable problem into programmable biology aimed at decoding biology to end disease.

The startup develops immunity-boosting proteins using artificial intelligence, immunology, computational biology, and protein engineering to create safe proteins that do not trigger immune responses. This technology enables physicians to prescribe products that are safe for individuals with food allergies and gluten-related disorders.

Manas AI develops medicines by integrating foundational AI technologies with deep domain expertise in biology and chemistry across the entire clinical pipeline. The company builds neuro-symbolic models that codify scientific rules to accelerate target identification, candidate generation, and optimization for various therapeutic modalities. This AI-augmented approach aims to deliver faster, more precise drug candidates through efficient preclinical testing and global clinical trials.

Enspire Bio is a drug discovery company utilizing advanced computational biology and machine learning techniques to identify novel therapeutic targets. The company addresses the inefficiencies in traditional drug development processes, aiming to accelerate the discovery of effective treatments for various diseases.

RewiredBio utilizes AI algorithms to analyze protein data, enabling researchers to gain insights into protein interactions and functions. This technology addresses the challenge of data complexity in biotechnology, facilitating more efficient drug discovery and development processes.

Tahoe provides a gigascale perturbative single‑cell platform that generates hundreds of millions of data points linking drug molecules to patient biology. The dataset fuels foundation AI models of virtual human cells, enabling target deconvolution and precision drug discovery, initially focused on oncology. Revenue is derived from licensing its proprietary datasets and AI models to pharmaceutical partners and from co‑development of therapeutics through joint ventures and collaborations.

Artivila Therapeutics utilizes an AI-powered drug discovery engine that integrates computational chemistry and synthetic biology to identify new drug targets in oncology, autoimmune diseases, and neurodegenerative disorders. The platform significantly reduces research and development costs and timelines while increasing the probability of successful drug outcomes for unmet medical needs.

Tianhu Technology specializes in computational chemistry and AI-driven protein design, focusing on enzyme modification and drug molecule development to enhance drug efficacy and reduce manufacturing costs. By leveraging extensive protein sequence data, the company delivers tailored solutions that improve product performance and shorten R&D cycles across various biopharmaceutical applications.

DenovAI Biotech utilizes artificial intelligence and computational molecular biophysics to design proteins tailored for specific applications in biotechnology. This approach addresses the challenge of time-consuming and costly protein development by streamlining the design process, enabling faster and more efficient production of functional proteins.

The startup is developing a discovery platform that utilizes advanced computational biology and machine learning to enhance the drug development process for complex age-related diseases. This platform addresses the inefficiencies and high costs associated with traditional drug discovery methods, aiming to accelerate the identification of viable therapeutic candidates.

Tushen Zhihe provides artificial intelligence-driven protein design services that utilize computational modeling and machine learning algorithms to optimize protein structures for specific functions. This technology addresses the challenges of traditional protein engineering by accelerating the design process and improving the accuracy of protein functionality predictions.

NeuroQBioAi develops advanced computational platforms for neuroscience research and drug discovery. The company leverages artificial intelligence and machine learning to analyze complex biological data sets. This capability accelerates the identification of novel therapeutic targets for neurological disorders.

Cellular Intelligence offers a platform that combines synthetic biology with computational design to create programmable cellular systems. Their workflow lets biotech and pharma companies model, synthesize, and test custom genetic circuits and pathways, reducing development time and variability for therapeutics, diagnostics, and industrial bioproducts.

Huili Bio is a synthetic biology platform that utilizes computational design to engineer enzymes for specific biochemical applications. The platform aims to enhance the efficiency of bioprocesses in industries such as pharmaceuticals and agriculture by providing tailored enzyme solutions.

Isomorphic Labs uses advanced AI models to accelerate drug discovery and design. Their predictive and generative AI systems unlock scientific insights and expedite the creation of novel therapeutic molecules, reducing the time and cost of bringing new medicines to market.

Deep Apple uses a deep learning platform that integrates cryo‑EM structural data, AI‑driven pocket extraction, molecular dynamics, and ultra‑high‑throughput virtual screening to identify small‑molecule candidates. The engine rapidly mines vast virtual chemical libraries to discover therapeutics for validated targets across inflammatory, immune, metabolic, and endocrine diseases. By combining advanced computational methods with structural biology, Deep Apple accelerates the early drug discovery timeline and expands the pool of viable drug candidates.

XtalPi is a pharmaceutical technology company that utilizes computational modeling and machine learning to predict drug interactions and properties, followed by experimental validation in wet labs. This approach reduces the time and cost associated with traditional drug discovery processes, enabling faster development of effective therapeutics.

Rare Molecule Foundry uses advanced AI models to design novel molecules, proteins, enzymes, and peptides in silico. This computational platform accelerates the discovery and optimization of compounds for biopharma and research applications. The company reduces time and uncertainty in the molecular innovation pipeline by providing precision-driven design before wet lab synthesis.

Phylo develops Biomni Lab, an integrated biology environment featuring collaborative AI agents designed for biomedical researchers. These agents execute complex scientific tasks, such as protein design and multi-omics data analysis, significantly accelerating discovery workflows. The platform ensures scientific rigor by reviewing steps for factual accuracy and maintaining transparent, reproducible research outputs.

Faeth Therapeutics utilizes computational biology and machine learning to develop multi-nodal nutritional treatments that target cancer metabolism, inhibiting cell growth through a comprehensive understanding of metabolic pathways. This approach addresses the limitations of traditional therapies by expanding the range of druggable targets within the cancer metabolism landscape.

Hologen offers an AI-powered platform that accelerates healthcare innovation by precisely modeling disease biology and individual patient differences. Its Large Medicine Models uncover subtle treatment effects and enable the design of personalized interventions for neurological disorders.

Artificial Intelligence Expert utilizes machine learning algorithms to analyze biomedical data, enhancing research accuracy and efficiency. The company addresses the challenge of data interpretation in the biomedical field, enabling researchers to derive actionable insights from complex datasets.

Genovo Technologies develops advanced computational biology platforms for drug discovery and development. The company specializes in leveraging machine learning and high-throughput screening to accelerate the identification of novel therapeutic candidates. Their technology aims to optimize preclinical research pipelines for pharmaceutical and biotech partners.

AminoAnalytica provides an AI-native operating system for computational protein design, enabling users to design novel proteins significantly faster without infrastructure setup. The platform offers flexible access through a CLI, a browser-based toolkit with 50+ essential tools like RFdiffusion, and integration with agentic systems for autonomous engineering workflows. Users gain on-demand access to enterprise-grade GPUs and pay only for compute resources used.

Inceptive utilizes large-scale deep learning to design RNA molecules that perform specific functions within biological systems. This approach enables the development of novel synthetic molecules for creating accessible medicines and biotechnologies that were previously unattainable.

This company develops and applies artificial intelligence tools, including expert systems and machine learning, to automate scientific practice. They focus on creating AI solutions that streamline complex research workflows. Future offerings include specialized AI tools designed for biologists to analyze experimental data efficiently.

Mechanica develops biotechnology companies by integrating computational biology and artificial intelligence into the drug discovery pipeline. The company focuses on leveraging the digitization of medicine to create new ventures and build shared infrastructure. This approach compounds biological insight across all of its programs to accelerate therapeutic development.

This company develops novel therapeutics by integrating quantum physics, causal biology, and multi-omics data with native-AI platforms. Their approach aims to accelerate drug discovery and enhance therapeutic precision for patient benefit. The core value lies in leveraging advanced computational and biological methods to create next-generation pharmaceutical candidates.

Deep Biologics utilizes artificial intelligence to enhance the discovery process of biologics, accelerating the development of therapeutic and diagnostic products. This approach addresses the lengthy timelines and high costs associated with traditional biologic development methods.

Symic Bio provides a synthetic biology platform that designs and assembles custom biological circuits to generate drug candidates across small‑molecule and biologic modalities. The system combines machine‑learning‑driven computational design, CRISPR‑compatible modular chassis, and automated high‑throughput screening, feeding results into a cloud‑native analytics suite for rapid lead identification and safety profiling. It targets pharmaceutical and biotech R&D teams seeking faster, more efficient discovery of high‑specificity therapeutics.

Silicogenix provides an AI‑native many‑to‑many discovery platform that simultaneously screens dozens of disease‑relevant targets, orthosteric and allosteric sites, and therapeutic modalities, generating drug‑like small molecules and peptide inhibitors with its CADDE chemistry engine. The end‑to‑end workflow integrates network biology analysis, hardware‑accelerated computation, and cloud analytics to deliver preclinical candidates in roughly three months for licensing or co‑development with pharmaceutical and biotech partners.

This company develops GeoFlow V3, a generative AI model that unifies the sequence, structure, and function of biomolecules for next-generation protein design. The platform accelerates the development of novel enzymes for sustainable bio-manufacturing and epitope-specific antibodies for biologics. This technology enables precise protein programming for applications in synthetic biology and biomedicine.

Greenstone Biosciences provides human iPSC-derived cells and 3D organoids to support New Approach Methods (NAMs) in drug discovery. The company offers custom cell engineering, high-throughput screening services, and proprietary AI platforms for preclinical validation. This integrated approach aims to accelerate the development of safer and more effective therapeutic candidates.

Deep Genomics utilizes a proprietary AI platform to analyze complex RNA biology data, identifying novel therapeutic targets for genetic conditions. By streamlining the drug discovery process, the company aims to develop RNA therapies that can precisely target genetic causes, significantly reducing the time and cost associated with traditional methods.

Brightseed utilizes its Forager® AI platform to identify and map bioactive compounds in plants, revealing their specific health benefits and connections to human biology. The company addresses the challenge of underutilized plant compounds by providing science-backed natural health solutions, such as its Bio Gut Fiber, which supports gut health through pre-clinical bioactive insights.

Onava integrates artificial intelligence with biological and human expertise to advance therapeutic development. The company focuses on leveraging advanced computational methods to enhance the discovery and optimization of new treatments. This approach aims to accelerate the pipeline for next-generation pharmaceutical solutions.

New Equilibrium Biosciences utilizes artificial intelligence to analyze biophysical data, enabling structure-based design in drug development. This platform identifies potential molecular candidates more efficiently, addressing the challenge of time-consuming and costly traditional drug discovery methods.

Akarso Bio develops a zero-calorie, clean-label prebiotic fiber platform that naturally stimulates GLP-1. This versatile ingredient helps food and beverage brands create products that enhance satiety, improve gut health, and support metabolic wellness. The platform enables manufacturers to innovate cost-effectively with functional ingredients that meet accelerating consumer demand.